New Covid-19 antivirals priced reasonably according to ICER
ICER's assessment is extremely unusual, since only 10% of reviewed drugs fell within ICER's cost-effectiveness threshold, as per a GlobalData…
By
Pricing and Market Access
Latest in
Pricing and Market Access
Precise magnitude of hospital markups revealed in the US
A recent study has shed light on the size of markups imposed by hospitals for parenteral cancer drugs in the…
By
FDA shows unease about marketing approval applications based on single-country trials
Several reasons specified in the ODAC rejection are specific to the sintilimab BLA.
By
Ukraine’s healthcare system – resilience under fire
Ukraine's health minister Viktor Lyashko pushes for 'business as usual' as Russia invades, but ingenuity and support are needed.
By
How horizon scanning can help predict the future for EU’s Alzheimer’s disease market
Aduhelm’s US launch has prompted a new look into what is in store for the Alzheimer’s disease market over the…
By
Pricing and Market Access Trends: 2022 Outlook
As we start 2022, the global market access environment has reached an unprecedented high level of risk.
By
Is price control by stealth the future for the United States?
There may be ways to introduce price control under federal drug programmes by stealth in the absence of state price…
By
Brukinsa: launch sequence of first Chinese cancer drug to roll out internationally
Two years after it received US FDA approval, BeiGene’s Brukinsa (zanubrutinib) has made steady progress around the world.
By